At a glance
- Originator Eisai Co Ltd
- Class Small molecules; Sulfonamides
- Mechanism of Action Dihydropteroate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 Nov 1997 No-Development-Reported for Cancer in Japan (Unknown route)
- 17 Nov 1995 Preclinical development for Cancer in Japan (Unknown route)